Paris, 16th September 2021: Ahead of the first Pharmapack Europe to be held in nearly 18-months, Informa has released the results of its global drug delivery and packaging survey, with the USA once again leading ‘drug delivery and device innovation’,…
AI ‘could help diagnose lung cancer a year earlier’
An artificial intelligence algorithm was able to detect signs of lung cancer on CT scans a year earlier than with traditional methods, according to a new study. CT (computed tomography) scans are already used to spot signs of lung tumours,…
MHRA cuts could affect UK regulatory decisions, say unions
A 20% to 25% reduction in staffing at the UK Medicines and Healthcare products Regulatory Agency (MHRA) risks undermining the ability of the authority to fulfil its role, according to trade unions. In an open letter to health secretary Sajid…
AbbVie spies potential in Regenxbio eye disease gene therapy
AbbVie has expanded its ophthalmology pipeline via a licensing deal with Regenxbio, paying $370 million upfront to get its hands on a gene therapy for wet age-related macular degeneration (AMD) and other eye diseases. The partnership centres on RGX314, which…
Zoll agrees $538m deal to buy sleep apnoea specialist Itamar
Itamar Medical was on the acquisition trail itself earlier this year, buying Spry Health to extend its sleep sensor technology range. Now, it’s being snapped up Zoll Medical in a deal valued at around $538 million. Israel-headquartered Itamar markets a…
AI aims to prevent unneeded treatment for deep vein thrombosis
Researchers in the UK are working on an artificial intelligence (AI) algorithm to help diagnose deep vein thrombosis (DVT) from ultrasound images – and potentially prevent patients from receiving drugs unnecessarily. The team from Oxford University, Imperial College London and…
First subject dosed in psilocybin trial for rare headache disorder
The first patient has received a low dose of Beckley Psytech’s psychedelic medicine psilocybin in a clinical trial for short-lasting unilateral neuralgiform headache attacks (SUNHA), a rare disorder. The UK company says that SUNHA is a debilitating condition that is…
Theravance axes staff as lead pipeline drug flunks phase 3 trial
Theravance has been forced to downsize its business after its lead pipeline drug ampreloxatine missed the mark in a phase 3 trial, cutting 75% of its workforce. The Irish-American biopharma said this morning that ampreloxetine did not meet its objectives…
